1241P Safety monitoring of adjuvant 2 weekly durvalumab for patients with stage III NSCLC: Implications for a 4 weekly regimen during the COVID-19 pandemic and beyond

por Joshi, K., Muhith, A., Milner-Watts, C., Obeid, M., Khakoo, S., Bhosle, J., Minchom, A.R., O'Brien, M.
Publicado 2020

180P Incidence of brain metastases (BM) in newly diagnosed stage IV NSCLC during COVID-19

por Cui, W., Milner-Watts, C., Saith, S., Bhosle, J., Minchom, A.R., Davidson, M., Page, S., Locke, I., Yousaf, N., Popat, S., O'Brien, M.E.R.
Publicado 2021